Why a new Alzheimer's drug is having a slow US debut

A year’s treatment will run about $26,500. Patients who can afford that without insurance will be able to start the treatment if they are deemed a candidate for Leqembi and they find a doctor and health care system prepared to help them.

Health insurers, which run Medicare Advantage coverage, have been sticking to that decision, said a spokesman for the trade group America’s Health Insurance Plans.its coverage stance, something the Alzheimer’s Association has urged it to do. Then the doctor has to decide what caused the condition. It could stem from Alzheimer’s, Parkinson’s disease, a stroke or a brain injury.

You could pass this meds. Let others choose by self. We need more capital on this field definitely.

Is it because the medical industry is price gouging it?

Claim it cures Covid. Will be on shelves next week.

Entertainment Entertainment Latest News, Entertainment Entertainment Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Why a new Alzheimer’s drug is having a slow U.S. debutThe first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. These seniors are better off dead.
Source: WashTimes - 🏆 235. / 63 Read more »

Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer's is on sale, but treatment for most patients is still several months away. Here's why.
Source: TucsonStar - 🏆 339. / 59 Read more »

Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer's is on sale, but treatment for most patients is still several months away. Here's why.
Source: dothaneagle - 🏆 337. / 59 Read more »